Astellas Pharma Europe B.V.
11 products tracked · names used in filings: Astellas Pharma Europe B.V., Astellas Pharma Europe B. V.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
No recent milestones.
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Izelvay avacincaptad pegol | Application withdrawn | |
| 🇪🇺 | Vibativ telavancin | Application withdrawn | |
| 🇪🇺 | Vyloy zolbetuximab | Authorised | 2024-09-19 |
| 🇪🇺 | Veoza fezolinetant | Authorised | 2023-12-07 |
| 🇪🇺 | Padcev enfortumab vedotin | Authorised | 2022-04-13 |
| 🇪🇺 | Evrenzo roxadustat | Authorised | 2021-08-18 |
| 🇪🇺 | Xospata gilteritinib | Authorised | 2019-10-24 |
| 🇪🇺 | Xtandi enzalutamide | Authorised | 2013-06-21 |
| 🇪🇺 | Betmiga mirabegron | Authorised | 2012-12-20 |
| 🇪🇺 | Modigraf tacrolimus | Authorised | 2009-05-15 |
| 🇪🇺 | Infergen interferon alfacon-1 | Withdrawn | 1999-02-01 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.